Company research
SOLENO THERAPEUTICS INC
CIK 1484565Updated Sep 25, 2026
SecuritySLNO · NASDAQ · equity
Historical securities (2)
CAPNW · NASDAQ · warrant · closed May 12, 2017SLNOW · NASDAQ · warrant · closed Dec 3, 2024Name history
Capnia, Inc. · through May 11, 2017
SLNO price & chart
Loading TradingView…
NASDAQ:SLNO on TradingView ↗About the company
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno’s first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
In the news
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO ↗
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit ↗
Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 563,830,000Source | 330,972,000Source | 180,691,000Source | 26,497,000Source |
| Property, Plant and Equipment, NetUSD | 185,000Source | 186,000Source | 12,000Source | 26,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 4,861,000Source | 6,805,000Source | 8,749,000Source | 10,693,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 70,106,000Source | 87,928,000Source | 169,681,000Source | 14,602,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 28,208,000Source | — | — | — |
| Inventory, NetUSD | 15,024,000Source | — | — | — |
| Assets, CurrentUSD | 355,814,000Source | 293,889,000Source | 171,358,000Source | 15,647,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,110,000Source | 2,452,000Source | 1,677,000Source | 1,045,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,191,000Source | 2,798,000Source | 407,000Source | 131,000Source |
| Other Assets, NoncurrentUSD | 163,000Source | 83,000Source | 165,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 113,715,000Source | 85,859,000Source | 23,184,000Source | 16,149,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 52,000Source | 46,000Source | 32,000Source | 8,000Source |
| Retained Earnings (Accumulated Deficit)USD | -431,370,000Source | -452,260,000Source | -276,410,000Source | -237,422,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 415,000Source | 361,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 450,115,000Source | 245,113,000Source | 157,507,000Source | 10,348,000Source |
| Additional Paid in Capital, Common StockUSD | 881,018,000Source | 696,966,000Source | 433,885,000Source | 247,762,000Source |
| Liabilities and EquityUSD | 563,830,000Source | 330,972,000Source | 180,691,000Source | 26,497,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 61,363,000Source | 18,747,000Source | 11,505,000Source | 7,313,000Source |
| Operating Lease, Liability, CurrentUSD | 726,000Source | 526,000Source | 273,000Source | 155,000Source |
| Accounts Payable, CurrentUSD | 12,435,000Source | 8,882,000Source | 3,149,000Source | 1,777,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,964,000Source | 2,472,000Source | 130,000Source | 0Source |
| Other Liabilities, NoncurrentUSD | 525,000Source | 21,000Source | — | — |
| Additional Financial Items | ||||
| Long-term Debt, Excluding Current MaturitiesUSD | 49,863,000Source | 49,828,000Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 20,890,000Source | -175,850,000Source | -38,988,000Source | -24,067,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 45,846,000Source | 99,958,000Source | 5,945,000Source | 2,530,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 28,208,000Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | 14,031,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 3,612,000Source | 5,672,000Source | 1,372,000Source | -1,477,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 46,798,000Source | -69,096,000Source | -24,940,000Source | -20,781,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -201,781,000Source | -225,682,000Source | 0Source | -13,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 73,000Source | 218,000Source | 0Source | 13,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 741,000Source | 0Source | 0Source | 16,000Source |
| Payments for Repurchase of Common StockUSD | 100,146,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 137,161,000Source | 213,025,000Source | 180,019,000Source | 14,092,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -17,822,000Source | -81,753,000Source | 155,079,000Source | -6,702,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 70,106,000Source | 87,928,000Source | 169,681,000Source | 14,602,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,534,000Source | — | — | — |
| Income Taxes Paid, NetUSD | 14,000Source | — | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | 1,900,000Source | 1,900,000Source | 1,900,000Source | 1,900,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 45,846,000Source | 99,958,000Source | 5,945,000Source | 2,530,000Source |
| Amortization of Debt Issuance CostsUSD | 35,000Source | — | — | — |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | 0Source | 0Source | — | — |
| DepreciationUSD | 73,000Source | 43,000Source | 14,000Source | 20,000Source |
| General and Administrative ExpenseUSD | — | 105,861,000Source | 13,481,000Source | 9,844,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | 5,476,000Source | 231,000Source | — | — |
| Investment Income, InterestUSD | 16,952,000Source | 12,052,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 20,890,000Source | -175,850,000Source | -38,988,000Source | -24,067,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 20,475,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 11,476,000Source | 11,821,000Source | 2,396,000Source | 330,000Source |
| Operating ExpensesUSD | 180,991,000Source | 187,671,000Source | 41,384,000Source | 24,397,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,578,000Source | 300,000Source |
| Proceeds from Issuance of Common StockUSD | 215,721,000Source | 148,955,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 49,888,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 17,202,000Source | 1,316,000Source | 347,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 190,405,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 132,128,000Source | — | — | — |
| Operating Income (Loss)USD | 9,414,000Source | -187,671,000Source | -41,384,000Source | -24,397,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,578,000Source | 300,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 20,890,000Source | -175,850,000Source | -38,988,000Source | -24,067,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | 20,890,000Source | -175,850,000Source | -38,988,000Source | -24,067,000Source |
| Earnings Per Share, BasicUSD per share | 0.4Source | -4.38Source | -2.36Source | -2.87Source |
| Earnings Per Share, DilutedUSD per share | 0.39Source | -4.38Source | -2.36Source | -2.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 50,817,586Source | 40,175,926Source | 16,492,132Source | 8,397,088Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 52,384,886Source | 40,175,926Source | 16,492,132Source | 8,397,088Source |
| Interest Expense (non-operating)USD | 5,476,000Source | 231,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 180,991,000Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,017,000Source | 1,987,000Source | 1,958,000Source | 1,964,000Source |
| General and Administrative ExpenseUSD | — | 105,861,000Source | 13,481,000Source | 9,844,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 20,253,000Source | -175,921,000Source | -39,180,000Source | -24,173,000Source |
| Interest Expense, DebtUSD | 5,476,000Source | — | — | — |
| Investment Income, InterestUSD | 16,952,000Source | 12,052,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 20,475,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 11,476,000Source | 11,821,000Source | 2,396,000Source | 330,000Source |
| Operating ExpensesUSD | 180,991,000Source | 187,671,000Source | 41,384,000Source | 24,397,000Source |
| Research and Development ExpenseUSD | 40,627,000Source | 78,568,000Source | 25,189,000Source | 15,265,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 190,405,000Source | — | — | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | -415,000Source | — | — | — |
Filing attachments
d142985dex991.htm · 8-K · 2026-04-06
EX-99.1 4 d142985dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio VYKAT TM XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine’s High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA ® (valbenazine) and CRENESSITY ® (crinecerfont) Establishes a Durable…
Read attachment ↗d110816dex991.htm · 8-K · 2026-02-26
EX-99.1 3 d110816dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer REDWOOD CITY, Calif., February 26, 2026 - Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he wi…
Read attachment ↗d251192dex991.htm · 8-K · 2026-02-25
EX-99.1 2 d251192dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR REDWOOD CITY, Calif., February 25, 2026 - Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update o…
Read attachment ↗d18767dex991.htm · 8-K · 2026-01-12
EX-99.1 2 d18767dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results REDWOOD CITY, Calif., January 12, 2026 - Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenu…
Read attachment ↗d63564dex991.htm · 8-K · 2025-11-12
EX-99.1 4 d63564dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement REDWOOD CITY, Calif., November 11, 2025 - Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has entered into an Accelerated Share Repurchase Agreement (“ASR”…
Read attachment ↗d58763dex991.htm · 8-K · 2025-11-04
EX-99.1 2 d58763dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR REDWOOD CITY, Calif., November 4, 2025 - Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM X…
Read attachment ↗